A pilot trial of combined chemotherapy with paclitaxel, doxorubicin and 
cisplatin was conducted in patients with advanced endometrial cancer. Between 
June 2000 and March 2002 8 patients were treated with combined chemotherapy, 
consisting of paclitaxel, 135 mg/m2; doxorubicin, 30 mg/m2; and cisplatin, 50 
mg/m2 (TAP therapy). Patients received 3 to 5 courses of TAP therapy every 4 
weeks. The major adverse effect was myelosuppression. All patients had grade 3 
or 4 neutropenia, but did not have any severe infection with uncontrollable 
fever. Only 1 patient discontinued additional therapy due to grade 3 
thrombocytopenia after 3 cycles. Grade 2 neurotoxicity occurred in 5 patients, 
but grade 3 was not observed. Among 5 patients with measurable tumors, 4 
achieved partial response and 1 had no change of tumor size, indicating a 
response rate of 80.0%. We found that TAP therapy was feasible with G-CSF 
support and shows potential for high efficacy in advanced endometrial cancer.